Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles

Modern Pathology

Volumn 27, Issue 1, 2014, Pages 128-134

  McConechy, Melissa K ^a   Ding, Jiarui ^a,b   Senz, Janine ^a   Yang, Winnie ^a   Melnyk, Nataliya ^a   Tone, Alicia A ^c   Prentice, Leah M ^a   Wiegand, Kimberly C ^a   McAlpine, Jessica N ^a   Shah, Sohrab P ^a,b   Lee, Cheng Han ^a   Goodfellow, Paul J ^d   Gilks, C Blake ^a   Huntsman, David G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

carcinoma; CTNNB1; endometrial; endometrioid; mutations; ovarian; PTEN

Indexed keywords

ARID1A PROTEIN; BETA CATENIN; CATENIN BETA 1; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PPP2R1A PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOMETRIAL ENDOMETRIOID CARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EPITHELIUM CELL; EXON; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATION RATE; OVARIAN ENDOMETRIOID CARCINOMA; OVARY CARCINOMA; OVARY CYST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

BETA CATENIN; CARCINOMA, ENDOMETRIOID; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASM GRADING; OVARIAN NEOPLASMS; PHENOTYPE; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84891747639     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.107     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide IARC CancerBase No. 10. International Agency for Research on Cancer: Lyon, France, 2010; http://globocan.iarc.fr.
3. Catasus L, Gallardo A, Prat J. Molecular genetics of endometrial carcinoma. Diagn Histopathol 2009;15: 554-563.
4. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010;2010:162363.
5. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004;35:649-662. (Pubitemid 38881074)
6. O'Hara AJ, Bell DW. The genomics and genetics of endometrial cancer. Adv Genomics Genet 2012;2: 33-47.
7. Chen S, Leitao MM, Tornos C, et al. Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol 2005;18:903-911. (Pubitemid 41059950)
8. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011;42:918-931.
9. McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011;223:567-573.
10. Prowse AH, Manek S, Varma R, et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 2006;119:556-562. (Pubitemid 43955708)
11. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18(Suppl 2):S19-S32. (Pubitemid 40188615)
12. Catasus L, Bussaglia E, Rodrguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004;35:1360-1368. (Pubitemid 39601576)
13. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012;228:20-30.
14. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-1760.
15. Ding J, Bashashati A, Roth A, et al. Feature-based classifiers for somatic mutation detection in tumournormal paired sequencing data. Bioinformatics 2012; 28:167-175.
16. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-D950.
17. Benjamini Y, Hochberg Y. Controlling the flse discovery rate-a practical and powerful approach to multiple testing. J Roy Stat Soc B Met 1995;57: 289-300.
18. Stuart GCE, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011;21:750-755.
19. Geyer JT, Lopez-Garcia MA, Sanchez-Estevez C, et al. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol 2009;33:1157-1163.
20. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011;43:420-432.
21. Shedden KA, Kshirsagar MP, Schwartz DR, et al. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 2005;11: 2123-2131. (Pubitemid 40490168)
22. Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58:1344-1347. (Pubitemid 28193586)
23. Gamallo C, Palacios J, Moreno G, et al. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999;155:527-536. (Pubitemid 29370402)
24. Wu R, Zhai Y, Fearon ER, et al. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001;61:8247-8255. (Pubitemid 33091619)
25. Wright K, Wilson P, Morland S, et al. Beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 1999;82:625-629. (Pubitemid 29356957)
26. Saegusa M, Okayasu I. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 2001;194: 59-67.
27. Sagae S, Kobayashi K, Nishioka Y, et al. Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn J Cancer Res 1999;90:510-515. (Pubitemid 29267704)
28. Moreno-Bueno G, Gamallo C, Perez-Gallego L, et al. Beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001;10: 116-122. (Pubitemid 32525880)
29. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000; 60:7052-7056. (Pubitemid 32059184)
30. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58:2095-2097. (Pubitemid 28232892)
31. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011;1:170-185.
32. Byron SA, Gartside M, Powell MA, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 2012;7:e30801.
33. Urick ME, Rudd ML, Godwin AK, et al. PIK3R1 (p85{alpha}) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011;71:4061-4067.
34. Shih IeM, Panuganti PK, Kuo KT, et al. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol 2011;178:1442-1447.
35. Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012;104:1503-1513.
36. Gallo ML, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012;44:1310-1315.
37. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
38. Jiang X, Morland SJ, Hitchcock A, et al. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 1998; 5:1707-1712. (Pubitemid 28215097)
39. Siiteri PK, Schwarz BE, MacDonald PC. Estrogen receptors and the estrone hypothesis in relation to endometrial and breast cancer. Gynecol Oncol 1974;2:228-238.
40. Key TJA, Pike MC. The dose-effect relationship between unopposed estrogens and endometrial mitotic rate-its central role in explaining and predicting endometrial cancer risk. Brit J Cancer 1988;57: 205-212. (Pubitemid 18085407)
41. Korner M, Burckhardt E, Mazzucchelli L. Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: a possible link to endometrioid adenocarcinoma. Mod Pathol 2006;19:1615-1623. (Pubitemid 44789930)
42. Giudice LC. Endometriosis. N Engl J Med 2010; 362:2389-2398.
43. Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008;14:32-40. (Pubitemid 351377975)
44. Van Langendonckt A, Casanas-Roux F, Dolmans MM, et al. Potential involvement of hemoglobin and heme in the pathogenesis of peritoneal endometriosis. Fertil Steril 2002;77:561-570. (Pubitemid 34177213)
45. Kobayashi H, Kajiwara H, Kanayama S, et al. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (Review). Oncol Rep 2009;22:233-240.
46. Vestergaard AL, Thorup K, Knudsen UB, et al. Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis. Mol Hum Reprod 2011;17:758-761.
47. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993;262:1734-1737. (Pubitemid 24030097)
48. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with beta-catenin. Science 1993;262:1731-1734. (Pubitemid 24030096)
49. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8:387-398. (Pubitemid 351589714)
50. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
51. Cully M, You H, Levine AJ, et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-192. (Pubitemid 43292562)
52. McCubrey JA, Steelman LS, Chappell WH, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades. Oncotarget 2012; 3:954-987.